Tadalafil
Brand names: Cialis, Adcirca
Tadalafil is an oral long-acting phosphodiesterase type-5 inhibitor used for erectile dysfunction and for the symptoms of benign prostatic hyperplasia, and (as a separate product) for pulmonary arterial hypertension.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively inhibits phosphodiesterase type-5, increasing cyclic GMP and enhancing nitric-oxide-mediated smooth muscle relaxation in the corpus cavernosum and lower urinary tract.
Prescribing in practice
- Co-administration with any nitrate or nicorandil is contraindicated because of the risk of profound, potentially fatal hypotension.
- Caution with alpha-blockers and other antihypertensives owing to additive blood-pressure lowering, and avoid in recent cardiovascular events or unstable angina.
- Dose adjustment or avoidance applies in severe renal or hepatic impairment and with potent CYP3A4 inhibitors.
Monitoring
Assess cardiovascular fitness for sexual activity before starting and review efficacy and tolerability, including any postural symptoms.
Counselling the patient
- Do not use with nitrate medicines or recreational nitrates ('poppers').
- Seek urgent care for a painful erection lasting several hours or for sudden visual or hearing loss.
Evidence & guidelines
Randomised trials support PDE5 inhibitors as first-line oral therapy for erectile dysfunction and demonstrate symptomatic benefit in benign prostatic hyperplasia.
Reference: NICE CG97; ESC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia